Please login to the form below

Not currently logged in
Email:
Password:

Neuway appoints Boehringer’s Baiker to board

He has 25 years’ experience at German pharma company

Wolfgang Baiker NeuwayBoehringer Ingelheim's Wolfgang Baiker was this week appointed to the advisory board of start-up biotech firm Neuway.

Baiker heads up the biopharmaceuticals and operations division at Boehringer and serves on the board of managing directors.

He was appointed to his current role in 2013 having previously served as corporate senior VP for development and in total Baiker has spent 25 years at Boehringer.

As board member at Neuway he will now help advise a fledgling company that was created in April 2014 as a spin-off from German research network the Life Science Inkubator.

Neuway intends to focus on the pre-clinical and clinical development of therapeutic treatment of rare brain diseases.

The company's CEO Stephan Rapp said: “Dr Baiker is one of the most successful and experienced managers in the area of development and production of innovative drugs in Germany.

“With this board position he is committing a considerable amount of his time to this project which has outstanding potential in the field of neurology.”

23rd July 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics